Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma

This study is testing whether adding the immunotherapy drug sintilimab to standard chemotherapy (plus a white blood cell booster called PEG-rhG-CSF) before surgery can improve outcomes for patients with esophageal squamous cell carcinoma — a type of esophageal cancer — that may be surgically removable. **You may be eligible if...** - You are age 18–75 with newly diagnosed esophageal squamous cell carcinoma confirmed by biopsy - Your cancer is located in the middle or lower esophagus and is potentially operable - You have not received any prior cancer treatment (surgery, chemo, radiation, or immunotherapy) - Your general health is good (ECOG 0–1) - Your blood counts, liver, kidney, and heart function are within acceptable ranges **You may NOT be eligible if...** - Your cancer has already spread to the neck lymph nodes or other organs - You have a history of other cancers in the past 5 years - You have active autoimmune disease or are on long-term steroid therapy - You are pregnant or breastfeeding - You have active hepatitis B or C, or HIV Talk to your doctor to see if this trial is right for you.